immunology/inflammation related

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

Galiximab (IDEC 114) is a primate-type anti-CD80 immunoglobulin G1 (IgG1)-like monoclonal antibody with antitumor activity that induces in vivo growth inhibition and prolongs survival of B-NHL tumor xenografts. Galiximab has been used in the study of hematologic malignancies.

Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affinity for CD123, CD32b/c, CD16-158F and CD16-158V, with KD of 0.43 nM, 188 nM, 46 nM and 16.8 nM, respectively. Talacotuzumab inhibits IL-3 signaling in target cells by inhibiting IL-3 binding to CD123. Talacotuzumab induces mutations in the Fc region to increase affinity for CD16 (FCγriiia), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab inhibits leukemia cell growth in xenografted mouse models of acute myeloid leukemia (AML).

Carotuximab (DE-122) is a novel endocholine antibody with strong antiangiogenic and anti-inflammatory activity. Carotuximab blocks endothelial glycoprotein (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antitumor effects to prevent human endothelial dysfunction induced by hypercholesterolemia and hyperglycemia.

Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.

Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.

Cudarolimab (IBI-101) is a fully human anti-OX40 antibody with potential immune checkpoint inhibitory and anti-tumor activity for the study of cancer.

Revdofilimab (ABBV-368) is a human IgG monoclonal antibody targeting Tumor Necrosis Factor Receptor superfamily member 4 (OX 40) with potential anticancer activity for the study of metastatic solid tumors and non-small cell lung cancer.

Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen. It exhibits anticancer activity by enhancing macrophage-associated phagocytosis of kidney cancer cells and inhibiting Burkitt lymphoma.

Telazorlimab (GBR-830) is a humanized monoclonal antibody targeting the OX40 co-stimulatory receptor on activated T cells, and is used to treat lupus erythematosus and atopic dermatitis.

Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized anti-CD33 monoclonal antibody that can be used for the synthesis of the ADC compound Vadastuximab talirine and for the study of acute myeloid leukemia (AML).

Ocrelizumab (IDC-2403) is a humanized monoclonal antibody directed against CD20 for the treatment of multiple sclerosis.

Icatolimab (JS-004) is a humanized antibody targeting BTLA/CD272 for the study of lymphomas and solid tumors.

Mirzotamab is an IgG1κ antibody targeting CD276/B7-H3 and is the naked antibody to Mirzotamab clezutoclax, consisting of 1320 amino acids.

Anti-Mouse CD28 Antibody (37.51) is a murine IgG-like antibody targeting CD28.

Omburtamab is a monoclonal antibody targeting CD276, often conjugated to 131 radioactive iodine ions, used for radioimmuno positron emission tomography studies.

Obexelimab (XmAb5871) is a bifunctional monoclonal antibody that binds CD19 and FcyRIIb, inhibits B-cells, plasmoblasts, and plasma cells, and may be used in the study of autoimmune diseases such as systemic lupus erythematosus.

Ibritumomab is a murine-derived anti-CD20 monoclonal antibody that kills tumor cells by forming free radicals in target cells and surrounding tissues.Ibritumomab is used in the study of non-Hodgkin's lymphoma.

Coltuximab is a humanized anti-CD19 antibody that can be used to synthesize ADC compounds (Coltuximab Ravtansine).

ABTIM3-hum11 is a humanized anti-TIM3 blood-brain barrier shuttling monoclonal antibody.

ABTIM3-hum03 is a humanized anti-TIM3 blood-brain barrier shuttling monoclonal antibody.

Lintuzumab (HuM-195) is a non-coupled humanized mouse monoclonal antibody directed against the cell-surface myelomonocyte differentiation antigen, CD33, with anti-leukemic activity that reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells.Lintuzumab has antitumor activity and induces cell death directly via CDC or ADCC. Lintuzumab has anti-tumor activity and induces cell death directly via CDC or ADCC.